Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Jurnal Farmasi Indonesia Jurnal Insan Farmasi Indonesia
Vitarani Dwi Ananda Ningrum
Universitas Islam Indonesia
Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Immunology & microbiology Medicine & Pharmacology Physics

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Efektivitas Terapi dan Kejadian Tidak Dikehendaki Penggunaan Regimen Pengobatan Jangka Pendek pada MultiDrug-Resistant Tuberculosis: a Scoping Review Yunilistianingsih - Yunilistianingsih; Vitarani Dwi Ananda Ningrum
Jurnal Farmasi Indonesia Vol 20 No 2 (2023): Jurnal Farmasi Indonesia
Publisher : Fakultas Farmasi Universitas Setia Budi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31001/jfi.v20i2.1970

Abstract

The increase in Multidrug-resistant Tuberculosis (MDR-TB) is a global problem that must be addressed immediately. Duration of treatment, adverse events (ADRs) and medical costs can affect adherence and treatment success. This literature review was conducted to review the effectiveness and ADRs of short-term regimens (STR) in MDR-TB patients. We used PubMed, ScienceDirect, and Google Scholar to retrieve the relevant original articles on MDR-TB treatment with STR in English-language, published from 2018 through 2022. The keywords used in the search for articles are "multi-drug-resistant tuberculosis", "short regimens" or "short-term regimens", effectiveness, safety" or "adverse events". Of the 13 articles obtained, the all-oral regimen proved promising for implementation in the treatment of MDR-TB. Based on sputum conversion, cure rate, and percentage of patients who completed treatment, the regimen with the highest therapeutic effectiveness was 6KmMfxPtoCfzHEZ/5MfxCfzEZ at 92.9%, and the lowest was 4KmMfxPtoCfzHEZ/5MfxCfzEZ at 63.6%. The all-oral regimen with or without Bedaquilin showed a better average therapeutic effectiveness (87.04%) than regimen containing injection (78.43%). Meanwhile, the serious ADRs that emerged were death, cardiotoxicity, hepatotoxicity and ototoxicity. Apart from monitoring the safety, research needs to be expanded to a larger population and wider sites, to find more effective regimens because Mycobacterium tuberculosis are easily resistant.
TINJAUAN NARATIF EFEKTIVITAS DAN KEAMANAN ANTIRETROVIRAL PADA PASIEN DENGAN KOINFEKSI HIV-HBV Rizky Yuliatus Solicha; Vitarani Dwi Ananda Ningrum
Jurnal Insan Farmasi Indonesia Vol 9 No 1 (2026): Jurnal Insan Farmasi Indonesia
Publisher : Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36387/phqp4b95

Abstract

HIV-HBV coinfection remains a major global health challenge associated with increased morbidity and mortality. Various studies have evaluated the effectiveness and safety of antiviral therapies in coinfected patients; however, the findings remain inconsistent. This narrative review aimed to summarize the current evidence regarding the effectiveness and safety of antiretroviral therapy in patients with HIV-HBV coinfection. Literature searches were conducted through PubMed and Google Scholar for studies published between 2014 and 2025 using keywords related to HIV, hepatitis B, nucleos(t)ide analogues, interferon alfa, effectiveness, and safety. The findings demonstrated that the TLD regimen (tenofovir, lamivudine, and dolutegravir) showed superior virological outcomes compared with TLE (tenofovir, lamivudine, and efavirenz), including higher viral suppression rates and greater CD4 cell recovery. Nucleos(t)ide analogues such as entecavir and telbivudine effectively reduced HBV DNA levels and improved liver function markers. However, several adverse drug reactions were reported, including dizziness, nausea, vomiting, metabolic disturbances, and renal impairment, particularly with tenofovir-containing regimens. Interferon alfa also demonstrated potential benefits in enhancing seroconversion. Overall, TLD is considered the preferred regimen due to its superior efficacy and resistance profile, although careful monitoring for adverse effects remains essential.
Co-Authors Rizky Yuliatus Solicha Yunilistianingsih - Yunilistianingsih